{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T06:18:09Z","timestamp":1783232289476,"version":"3.54.6"},"posted":{"date-parts":[[2026,5,21]]},"group-title":"Hematology","reference-count":41,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Modern therapy for childhood and adolescent leukemia requires accurate risk classification of genomic subtype. Although short-read next-generation sequencing (NGS)-based approaches provide comprehensive clinical diagnostics in limited, highly resourced settings, they remain expensive, slow, and inaccessible to most children worldwide. Transformative approaches are needed to improve diagnostic classification for leukemia globally.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We simultaneously continued to develop an analytical pipeline NASVar (Nanopore variant calling for adaptive sampling), and conducted a multicenter, type-two hybrid clinical validation study of an Oxford Nanopore Technologies (ONT) adaptive-sampling whole-genome sequencing (asWGS) assay across hospitals with varying diagnostic resources. In preparation for implementation, a global panel developed a leukemia-based standardized gene set and consensus laboratory-developed test (LDT) validation guidelines. Measures of assay effectiveness compared to both conventional and orthogonal NGS methods, where available, were simultaneously collected with data to measure the implementation outcomes of feasibility, fidelity, appropriateness, and cost.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All four centers successfully completed the LDT validation, with minimal adaptations required for regulatory compliance. A total of 457 specimens were sequenced (331 B-ALL, 83 AML, 43 T-ALL). For the 210 B-ALL cases with locally resolved genomic subtypes defined by DNA alterations, asWGS was 100% concordant (210\/210). Cases locally defined as B-other were resolved via asWGS with disease-defining DNA alterations in 47% (49\/105) of cases. An additional 41% (43\/105) of locally defined B-other cases were classified by incorporation of DNA methylation, and all 16 B-ALL patient-derived xenograft controls were correct, for a total of 96% (318\/331) of all B-ALL cases in the cohort resolved with single assay asWGS. For AML, 97% (56\/58) of cases with locally resolved genomic subtypes were identified by automated asWGS analysis, while an additional two cases were identified after targeted manual review. At Indus Hospital in Pakistan, the B-ALL and AML diagnostic genomic subtype yield increased from 28% with local standard of care diagnostic testing, to 84% with asWGS. The cost of reagents and consumables in the United States, assuming pooled three-plexing, was $343\/sample. Based on the combined hybrid validation results, all centers are independently preparing for clinical return of results.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ONT asWGS was successfully validated as a clinical assay in four diverse hospital settings. As a single, multi-omic platform that delivers value across the continuum of high-resource to resource-limited contexts, the approach offers a disruptive solution to address the global equity gap in cancer diagnostics.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.05.19.26353434","type":"posted-content","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T22:40:17Z","timestamp":1779403217000},"source":"Crossref","is-referenced-by-count":1,"title":["Addressing the Global Diagnostics Gap for Childhood Leukemias: A Global, Multisite Type 2 Hybrid Validation Study of Nanopore-based Adaptive Sampling Whole Genome Sequencing"],"prefix":"10.64898","author":[{"given":"Thomas B.","family":"Alexander","sequence":"first","affiliation":[{"name":"University of North Carolina, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubina","family":"Islam","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Center, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeria","family":"Aijaz","sequence":"additional","affiliation":[{"name":"Indus Health and Hospital Network, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Bolous","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital, TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlijn","family":"Cammel","sequence":"additional","affiliation":[{"name":"Princess Maxima Center, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Geyer","sequence":"additional","affiliation":[{"name":"University of North Carolina, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Gray","sequence":"additional","affiliation":[{"name":"University of North Carolina, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakir","family":"Hussain","sequence":"additional","affiliation":[{"name":"Indus Health and Hospital Network, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Imran","sequence":"additional","affiliation":[{"name":"Indus Health and Hospital Network, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Jamal","sequence":"additional","affiliation":[{"name":"Indus Health and Hospital Network, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijita","family":"Kar","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Center, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dona","family":"Kanavy","sequence":"additional","affiliation":[{"name":"University of North Carolina, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelum","family":"Mansoor","sequence":"additional","affiliation":[{"name":"Indus Health and Hospital Network, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Parihar","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Center, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaskar","family":"Saha","sequence":"additional","affiliation":[{"name":"Tata Translational Cancer Research Center, Kolkata, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan","family":"Tops","sequence":"additional","affiliation":[{"name":"Princess Maxima Center, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wilkins","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital, TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Weck","sequence":"additional","affiliation":[{"name":"University of North Carolina, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital, TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhou","sequence":"additional","affiliation":[{"name":"University of North Carolina, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Kester","sequence":"additional","affiliation":[{"name":"Princess Maxima Center, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Wang","sequence":"additional","affiliation":[{"name":"University of North Carolina, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickhill","family":"Bhakta","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital, TN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"issue":"10536","key":"2026052308301367000_2026.05.19.26353434v1.1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(26)00189-3","article-title":"Progress towards the WHO Global Initiative for Childhood Cancer target of 60% 5-year survival for all childhood cancers combined, 1990-2019 (CONCORD-4): a Cancer Survival Index derived for 68 countries by analysis of individual records for 613lJ021 children from 307 population-based cancer registries","volume":"407","year":"2026","journal-title":"Lancet"},{"key":"2026052308301367000_2026.05.19.26353434v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30031-2"},{"key":"2026052308301367000_2026.05.19.26353434v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411680"},{"key":"2026052308301367000_2026.05.19.26353434v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"issue":"2","key":"2026052308301367000_2026.05.19.26353434v1.5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.6004\/jnccn.2025.0006","article-title":"Pediatric acute lymphoblastic leukemia, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"2026052308301367000_2026.05.19.26353434v1.6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood.2024027904","article-title":"Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel","volume":"147","year":"2026","journal-title":"Blood"},{"issue":"5","key":"2026052308301367000_2026.05.19.26353434v1.7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1470-2045(25)00146-9","article-title":"The Global Platform for Access to Childhood Cancer Medicines: addressing inequities in childhood cancer care","volume":"26","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026052308301367000_2026.05.19.26353434v1.8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02238"},{"key":"2026052308301367000_2026.05.19.26353434v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2023.09.013"},{"issue":"15","key":"2026052308301367000_2026.05.19.26353434v1.10","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/bloodadvances.2022008992","article-title":"Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia","volume":"7","year":"2023","journal-title":"Blood Adv"},{"key":"2026052308301367000_2026.05.19.26353434v1.11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08635-5"},{"key":"2026052308301367000_2026.05.19.26353434v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01806-8"},{"issue":"4","key":"2026052308301367000_2026.05.19.26353434v1.13","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S1470-2045(20)30022-X","article-title":"Sustainable care for children with cancer: a Lancet Oncology Commission","volume":"21","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026052308301367000_2026.05.19.26353434v1.14","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(18)30761-7","article-title":"Childhood cancer burden: a review of global estimates","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026052308301367000_2026.05.19.26353434v1.15","doi-asserted-by":"crossref","first-page":"e0314592","DOI":"10.1371\/journal.pone.0314592","article-title":"Trends in childhood cancer: Incidence and survival analysis over 45 years of SEER data","volume":"20","year":"2025","journal-title":"PLoS ONE"},{"key":"2026052308301367000_2026.05.19.26353434v1.16","doi-asserted-by":"crossref","unstructured":"Busby KM , Webb N , Aijaz J , Antillon-Klussmann F , Saha V , Reis RM , et al. Facilitators and Barriers for Implementing Diagnostic Sequencing Technology for Pediatric Oncology in Low- and Middle-Income Countries. Pediatr Blood Cancer. 2026 Mar 15;e70207.","DOI":"10.22541\/au.175673365.53679045\/v1"},{"key":"2026052308301367000_2026.05.19.26353434v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02565-y"},{"key":"2026052308301367000_2026.05.19.26353434v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02321-z"},{"issue":"1","key":"2026052308301367000_2026.05.19.26353434v1.19","doi-asserted-by":"crossref","first-page":"6961","DOI":"10.1038\/s41467-025-62005-4","article-title":"Epigenomic diagnosis and prognosis of Acute Myeloid Leukemia","volume":"16","year":"2025","journal-title":"Nat Commun"},{"key":"2026052308301367000_2026.05.19.26353434v1.20","doi-asserted-by":"crossref","unstructured":"Achterberg T , de Ruijter E , van Tuil, M , Waanders, E , Goemans B , Calkoen, F , et al. Rapid DNA-methylation based classification of hematological malignancies. Blood. 2025;146.","DOI":"10.1182\/blood-2025-119"},{"key":"2026052308301367000_2026.05.19.26353434v1.21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty191"},{"key":"2026052308301367000_2026.05.19.26353434v1.22","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-019-0898-y"},{"key":"2026052308301367000_2026.05.19.26353434v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0618-7"},{"issue":"11","key":"2026052308301367000_2026.05.19.26353434v1.24","doi-asserted-by":"crossref","first-page":"e828","DOI":"10.1016\/S2352-3026(21)00304-5","article-title":"Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97\/99 and UKALL2003 clinical trials","volume":"8","year":"2021","journal-title":"Lancet Haematol"},{"key":"2026052308301367000_2026.05.19.26353434v1.25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004895"},{"key":"2026052308301367000_2026.05.19.26353434v1.26","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD.2023023120"},{"key":"2026052308301367000_2026.05.19.26353434v1.27","doi-asserted-by":"crossref","first-page":"871590","DOI":"10.3389\/fonc.2022.871590","article-title":"Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis","volume":"12","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"2026052308301367000_2026.05.19.26353434v1.28","doi-asserted-by":"crossref","first-page":"e2516296","DOI":"10.1001\/jamanetworkopen.2025.16296","article-title":"Cytarabine pharmacogenomics and outcomes among children and young adults with acute myeloid leukemia","volume":"8","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026052308301367000_2026.05.19.26353434v1.29","unstructured":"Karol S . Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia\/Lymphoma [Internet]. ClincalTrials.gove. 2024 [cited 2026 Apr 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06289673"},{"key":"2026052308301367000_2026.05.19.26353434v1.30","unstructured":"Karol S . Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma [Internet]. ClinicalTrials.gov. 2024 [cited 2026 Apr 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06533748"},{"key":"2026052308301367000_2026.05.19.26353434v1.31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1800"},{"key":"2026052308301367000_2026.05.19.26353434v1.32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281653"},{"key":"2026052308301367000_2026.05.19.26353434v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00673-5"},{"key":"2026052308301367000_2026.05.19.26353434v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30459-8"},{"key":"2026052308301367000_2026.05.19.26353434v1.35","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-022-03448-8"},{"key":"2026052308301367000_2026.05.19.26353434v1.36","unstructured":"World Health Organization. CureAll framework: WHO Global Initiative for Childhood Cancer. Increasing access, advancing quality, saving lives. 2021;"},{"key":"2026052308301367000_2026.05.19.26353434v1.37","unstructured":"World Health Organization. Political declaration of the fourth high-level meeting of the General Assembly on the prevention and control of noncommunicable diseases and the promotion of mental health and well-being. WHO; 2025 Dec."},{"key":"2026052308301367000_2026.05.19.26353434v1.38","unstructured":"International Atomic Energy Agency. IAEA and St. Jude Children\u2019s Research Hospital Partner to Bridge Gap in Global Childhood Cancer Care [Internet]. 2025 [cited 2026 Apr 13]. Available from: https:\/\/www.iaea.org\/newscenter\/pressreleases\/iaea-and-st-jude-childrens-research-hospital-partner-to-bridge-gap-in-global-childhood-cancer-care"},{"key":"2026052308301367000_2026.05.19.26353434v1.39","unstructured":"NCDconnect. NCDconnect & ACT for Children: Closing the Paediatric Cancer Gap [Internet]. 2025 [cited 2026 Apr 12]. Available from: https:\/\/ncdconnect.org\/en\/ncdconnect-act-for-children-paediatric-cancer-gap-news\/"},{"issue":"2","key":"2026052308301367000_2026.05.19.26353434v1.40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cncr.35065","article-title":"The role of relative advantage for development of sequencing-based diagnostics for pediatric cancer in low- and middle-income countries","volume":"130","year":"2024","journal-title":"Cancer"},{"issue":"1","key":"2026052308301367000_2026.05.19.26353434v1.41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43058-025-00831-9","article-title":"So what? Elevating the impact of implementation science","volume":"7","year":"2025","journal-title":"Implement Sci Commun"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.05.19.26353434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T15:30:18Z","timestamp":1779550218000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.05.19.26353434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":41,"URL":"https:\/\/doi.org\/10.64898\/2026.05.19.26353434","relation":{},"subject":[],"published":{"date-parts":[[2026,5,21]]},"subtype":"preprint"}}